Eli Lilly (LLY.N): Pediatric ulcerative colitis data add another avenue for Omvoh growth

Omvoh's positive phase 3 SHINE-2 results in pediatric ulcerative colitis (UC) reinforce the asset's durable efficacy and should provide another avenue for incremental growth within Lilly's established immunology franchise. Among induction responders, 50% achieved clinical remission at Week 52, consistent with the 50.7% reported among adult responders in phase 3 LUCENT-2, while 50% achieved corticosteroid-free remission without surgery. Global regulatory submissions are planned, and approval would make Omvoh the first selective IL-23p19 inhibitor in pediatric UC. J&J's Stelara and lower-cost ustekinumab biosimilars create a competitive market, but Omvoh's prospective pediatric dataset, selective mechanism, and consistency across age groups should support use among patients requiring advanced therapy. While the label expansion is unlikely to materially change Lilly's revenue outlook alone, it strengthens Omvoh's lifecycle and reinforces the I&I portfolio as a healthy growth contributor (